| Revista: | Biotecnología aplicada |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000349776 |
| ISSN: | 0864-4551 |
| Autores: | Sánchez, Belinda1 Aguiar, Yeranddy1 Hernández, Diana R1 Garrido, Greta1 Pérez, Rolando1 Fernández, Luis E1 |
| Instituciones: | 1Centro de Inmunología Molecular, La Habana. Cuba |
| Año: | 2009 |
| Volumen: | 26 |
| Número: | 4 |
| Paginación: | 342-344 |
| País: | Cuba |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | The Epidermal Growth Factor Receptor (EGFR) plays an essential role in regulating neoplastic processes. EGFR over-expression in many human epithelial tumors has been correlated with disease progression and bad prognosis. Passive EGFR-directed immunotherapy has been introduced in medical oncology practice, but no active specific approaches have been used. We designed a vaccine candidate based on the extracellular domain (ECD) of human EGFR (HER1), and the homologous vaccine for mice based on murine EGFR. This vaccine candidate uses the Very Small-Sized Proteoliposomes from Neisseria meningitidis (VSSP) and Montanide ISA 51-VG as adjuvants. The autologous vaccine circumvents the tolerance to self EGFR by inducing a specific immune response with an anti-metastatic effect on EGFR+ tumors. The vaccine candidate based on HER1-ECD induced anti-EGFR polyclonal antibodies (PAb) that bind EGFR+ human tumor cell lines from different tissues. These anti-EGFR PAb abrogate ligand-dependent EGFR phosphorylation, provoking the inhibition of tumor cell growth and apoptosis. Preclinical results further encouraged the evaluation of the HER1 vaccine candidate in phase I clinical trials |
| Disciplinas: | Medicina |
| Palabras clave: | Oncología, Inmunología, Tumores epiteliales, Vacunas, Factor de crecimiento epidérmico |
| Keyword: | Medicine, Oncology, Immunology, Epithelial tumors, Vaccines, Epidermal growth factor |
| Texto completo: | Texto completo (Ver PDF) |
